AlphaQuest LLC Purchases 2,964 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)

AlphaQuest LLC lifted its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 469.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,596 shares of the company’s stock after buying an additional 2,964 shares during the quarter. AlphaQuest LLC’s holdings in Keros Therapeutics were worth $57,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in KROS. Geode Capital Management LLC lifted its holdings in Keros Therapeutics by 6.8% during the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock valued at $42,146,000 after purchasing an additional 46,041 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock valued at $15,105,000 after purchasing an additional 32,492 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Keros Therapeutics during the 4th quarter valued at $388,000. Barclays PLC lifted its holdings in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company’s stock valued at $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Keros Therapeutics during the 3rd quarter valued at $603,000. 71.56% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on KROS. HC Wainwright dropped their target price on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Scotiabank dropped their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. TD Cowen downgraded Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Wedbush downgraded Keros Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $47.00 to $15.00 in a research note on Friday, January 17th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Stock Up 0.2 %

Keros Therapeutics stock opened at $11.44 on Friday. Keros Therapeutics, Inc. has a 12-month low of $9.78 and a 12-month high of $72.37. The business’s 50-day moving average price is $11.25 and its two-hundred day moving average price is $36.24. The stock has a market cap of $464.03 million, a PE ratio of -2.20 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.